Terbinafine: an update.
Oral terbinafine was first introduced in the United Kingdom in February 1991 and was approved for the treatment of onychomycosis in the United States in May 1996. It is estimated that 4 million patients worldwide have been treated with oral terbinafine as of December 1996. The efficacy of terbinafine in the treatment of onychomycosis and other dermatomycoses is reviewed. The adverse-effects profile of oral terbinafine is evaluated.
Gupta
A K
AK
Department of Medicine, Sunnybrook Health Science Center, Toronto, Canada.
Shear
N H
NH
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003881:Dermatomycoses / Q000188:drug therapy; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D009281:Naphthalenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014009:Onychomycosis / Q000188:drug therapy*; D011247:Pregnancy; D011358:Product Surveillance, Postmarketing; D000077291:Terbinafine; D014005:Tinea / Q000188:drug therapy; D006113:United Kingdom; D014481:United States
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine